Acasti Pharma(ACST) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update • Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 • Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2026 Princeton, NJ, August 9, 2024 (GLOBE NEWSWIRE)-- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), ...